Hayden E. Klein

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.

Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society (ATS) 2025 International Conference.

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared with placebo.

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.

The goal of the proposed bill is to “make prescriptions affordable again” in the US.

Sexual minority individuals face countless barriers to health care and are at a heightened risk of unwanted pregnancy.

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual Scientific Session.

New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

Panelists explored responsible, patient-centered use of artificial intelligence (AI) in cardiovascular care at the American College of Cardiology 2025 Annual Scientific Session.

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

MACRO trial researchers said adapting to the COVID-19 pandemic mid-trial may have undercut the efficacy of the intervention, but it still showed promise.

Despite showing no overall benefit, an in-home paramedic visit appeared to help women avoid readmissions more than men.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type 2 diabetes.

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, elevated heart failure risk after ovary removal, and more.

New research suggests areas with higher concentrations of microplastics also have higher rates of chronic disease.

A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.

One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White women.

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

Jorge García, PharmD, MS, MBA, MHA, highlights the need for infusion pharmacy optimization to sustain oncology care amid rising costs and evolving value-based reimbursement models.

Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.